pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
Vertex Pharmaceuticals (Australia) projects
5 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).
Vertex Pharmaceuticals (Australia) has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
LUM/IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
8 trials -
Suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Pain
6 trials -
Suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Acute Pain
2 trials -
Telaprevir
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C
11 trials -
suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Pain, Acute Postoperative
1 trial
Frequently asked questions
How many clinical projects does Vertex Pharmaceuticals (Australia) have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.